Immunotherapy Drug Can Lower Recurrence When Bladder Cancer Spreads
Matthew Galsky, MD, discusses his long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer. He said, “These results support adjuvant nivolumab as a standard of care for high-risk [patient with] muscle-invasive urothelial carcinoma after radical surgery.
![Building exterior](/files/MSHealth/Assets/Global/Newsroom/2021/ISMMS-Spotlight-Placeholder-2col-770x420-2.jpg)
Researchers Discover Why One Type of Chemotherapy Works Best in Bladder Cancer
Jan 26, 2024 View All Press Releases![New York skyscrapers](/files/MSHealth/Assets/Global/Newsroom/2021/ISMMS-Spotlight-Placeholder-2col-770x420-3.jpg)
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press ReleasesCombination of Chemo and Immunotherapy Is Shown to Work Against Metastatic Bladder Cancer
May 15, 2020 View All Press Releases